ofloxacin has been researched along with Dizziness in 3 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study concluded that the dosage regimen of LVFX 500 mg once daily was effective and tolerable for the treatment of LRTIs and UTIs." | 6.74 | Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. ( Chen, BY; Ding, GH; Duan, J; Gu, JM; Guo, DY; Hao, QL; Huang, HH; Huang, JA; Li, HY; Li, QH; Liu, A; Lü, XJ; Ma, H; Ren, ZY; Shen, HH; Shi, MH; Si, B; Sun, SH; Sun, TY; Wu, GM; Xia, QM; Xiao, W; Xiao, ZK; Xiu, QY; Yang, HF; Yang, HP; Yao, WZ; Ying, KJ; Yu, YS; Yue, HM; Zhang, W; Zhang, YY; Zheng, HG, 2009) |
| " This study concluded that the dosage regimen of LVFX 500 mg once daily was effective and tolerable for the treatment of LRTIs and UTIs." | 2.74 | Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. ( Chen, BY; Ding, GH; Duan, J; Gu, JM; Guo, DY; Hao, QL; Huang, HH; Huang, JA; Li, HY; Li, QH; Liu, A; Lü, XJ; Ma, H; Ren, ZY; Shen, HH; Shi, MH; Si, B; Sun, SH; Sun, TY; Wu, GM; Xia, QM; Xiao, W; Xiao, ZK; Xiu, QY; Yang, HF; Yang, HP; Yao, WZ; Ying, KJ; Yu, YS; Yue, HM; Zhang, W; Zhang, YY; Zheng, HG, 2009) |
| " Periodic and continuous ECGs were recorded before and after subjects were dosed with placebo and increasing doses of levofloxacin (500 mg, 1000 mg, 1500 mg) that included doses twice the maximum recommended dose of 750 mg in a double-blind, randomized, four-period, four-sequence crossover trial." | 2.71 | Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. ( Chien, S; Goodman, DB; Natarajan, J; Noel, GJ; Padmanabhan, M; Solanki, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, YY | 1 |
| Huang, HH | 1 |
| Ren, ZY | 1 |
| Zheng, HG | 1 |
| Yu, YS | 1 |
| Lü, XJ | 1 |
| Xiao, ZK | 1 |
| Yang, HF | 1 |
| Xiu, QY | 1 |
| Chen, BY | 1 |
| Yue, HM | 1 |
| Hao, QL | 1 |
| Huang, JA | 1 |
| Ma, H | 1 |
| Xiao, W | 1 |
| Guo, DY | 1 |
| Si, B | 1 |
| Sun, SH | 1 |
| Zhang, W | 1 |
| Li, QH | 1 |
| Shen, HH | 1 |
| Duan, J | 1 |
| Li, HY | 1 |
| Yao, WZ | 1 |
| Gu, JM | 1 |
| Xia, QM | 1 |
| Ying, KJ | 1 |
| Liu, A | 1 |
| Yang, HP | 1 |
| Shi, MH | 1 |
| Sun, TY | 1 |
| Ding, GH | 1 |
| Wu, GM | 1 |
| Noel, GJ | 1 |
| Goodman, DB | 1 |
| Chien, S | 1 |
| Solanki, B | 1 |
| Padmanabhan, M | 1 |
| Natarajan, J | 1 |
| Stahlmann, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ofloxacin and Dizziness
| Article | Year |
|---|---|
Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
Topics: Administration, Oral; Adolescent; Aged; Anti-Bacterial Agents; China; Dizziness; Drug Administration | 2009 |
Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Cross-Over Studies; Dizziness; Dose-Response Re | 2004 |
1 other study available for ofloxacin and Dizziness
| Article | Year |
|---|---|
Clinical toxicological aspects of fluoroquinolones.
Topics: Anti-Infective Agents; Bacterial Infections; Cardiovascular Diseases; Central Nervous System Disease | 2002 |